(Q55474881)

12 July 2018

title

Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors. (English)

1 reference

12 July 2018

1 reference

Park JR

1

1 reference

12 July 2018

Slattery J

2

1 reference

12 July 2018

Gooley T

3

1 reference

12 July 2018

Hawkins D

4

1 reference

12 July 2018

Lindsley K

5

1 reference

12 July 2018

Villablanca JG

6

1 reference

12 July 2018

Matthay KK

7

1 reference

12 July 2018

Sanders JE

8

1 reference

12 July 2018

publication date

1 December 2000

1 reference

12 July 2018

published in

Pediatric Blood Cancer

1 reference

12 July 2018

volume

35

1 reference

12 July 2018

page(s)

719-723

1 reference

12 July 2018

issue

6

1 reference

12 July 2018

Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Surveillance scanning of children with medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

High-dose chemotherapy and autologous bone marrow rescue followed by interstitial and external-beam radiotherapy in newly diagnosed pediatric malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1096-911X%2820001201%2935%3A6%3C719%3A%3AAID-MPO52%3E3.0.CO%3B2-V

10.1002/1096-911X(20001201)35:6<719::AID-MPO52>3.0.CO;2-V

21 January 2018

Identifiers

DOI

1 reference

12 July 2018

release_esnx73qqhbhwzaangi5q6kdtou

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/esnx73qqhbhwzaangi5q6kdtou

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

11107155

1 reference

12 July 2018